drugset / Trial / NCT06158386
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
Phase 2
Recruiting
33 enrolled
The First Affiliated Hospital of Xiamen University
Dongguan People's Hospital · collabFujian Cancer Hospital · collabFujian Provincial Hospital · collabHuizhou Municipal Central Hospital · collabJieyang People's Hospital · collabShanxi Province Cancer Hospital · collabSun Yat-sen University · collabThe First Affiliated Hospital with Nanjing Medical University · collabZhangzhou Affiliated Hospital of Fujian Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
To observe the safety and efficacy of Chidamide combined with Linperlisib in the treatment of refractory and relapsed follicular lymphoma.
Timeline
- Start
- 2023-11-22
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Linperlisib | Small molecule | 80 mg | — |
| Subject | Tucidinostat | Small molecule | 20 mg | Oral |